Pharma BD Deal Intelligence
The Amgen Fremont facility currently employs approximately 360 employees and is a state-of-the-art manufacturing facility; Boehringer had been a contract…
Boehringer formally acquired Amgen's Fremont development and manufacturing facility, leasing buildings and acquiring equipment; the site employed more than…
Contract Pharma analysis framed the deal as accretive to BI's biopharma CMO franchise — solving a US capacity gap during a period of rising mammalian-cell…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Boehringer Ingelheim acquired Amgen's Fremont, California biologics manufacturing facility, expanding Boehringer's biopharma contract manufacturing capacity. Closed March 2011. Financial terms not disclosed.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) (this deal) | 2011 | — | 77 |
| Boehringer Ingelheim GmbH / NBE Therapeutics | 2020 | $1.5B | 28 |
| Boehringer Ingelheim GmbH / AMAL Therapeutics SA | 2019 | $366M | — |
| Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. | 2019 | $1.2B | — |
| Boehringer Ingelheim GmbH / NBE-Therapeutics AG | 2020 | $1.4B | — |
| Boehringer Ingelheim GmbH / Yuhan Corporation | 2019 | $870M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
← Browse all deals · How we score deals
More: 2011 deals · Boehringer Ingelheim GmbH deals · Other deals